Ruchhoft E A, Elkind-Hirsch K E, Malinak R
Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas.
Fertil Steril. 1996 Jul;66(1):54-60. doi: 10.1016/s0015-0282(16)58387-3.
To determine if continuous oral contraceptive (OC) therapy was superior to a cyclic regimen in achieving persistent pituitary suppression of LH in patients with polycystic ovary syndrome (PCOS).
Fourteen women (ages 16 to 41 years) with PCOS received one of three treatment groups: continuous OC therapy (30 micrograms ethinyl E2 plus 150 micrograms desogestrel), cyclic OC therapy, or monthly injections of a GnRH agonist (GnRH-a, leuprolide acetate depot 3.75 mg) for 3 months. Basal hormone levels were obtained before initiating therapy, on days 15 to 17 of the 3rd month of treatment (study 1) and again on days 26 to 28 of the 3rd month (study 2). A GnRH stimulation test was also performed during study 1 and study 2.
After 3 months of treatment, LH levels were decreased significantly in all groups with less effective suppression observed in the cyclic OC group compared with the continuous OC or GnRH-a groups. A significant rise in LH was found only in the cyclic OC group after 5 to 7 days of placebo treatment (study 1 versus study 2). An increase in T was also observed in the cyclic OC group during study 2, whereas the continuous OC and GnRH-a groups showed continued inhibition of T levels. Although there was no significant difference in LH area under the curve (AUC) measurements after GnRH stimulation in study 1 versus study 2, the LH AUC was significantly greater in both studies in the cyclic OC group compared with the continuous OC or GnRH-a groups.
Increased LH secretion during the week of placebo in the cyclic OC group was associated with a concomitant increase in T. The striking rise in LH secretion after GnRH stimulation in the cyclic OC group may represent increased pituitary sensitivity in patients receiving cyclic OCs regardless of the phase of the treatment cycle, perhaps secondary to increased pituitary stores of LH in these women.
确定在多囊卵巢综合征(PCOS)患者中,持续口服避孕药(OC)疗法在实现垂体对促黄体生成素(LH)的持续抑制方面是否优于周期疗法。
14名年龄在16至41岁的PCOS女性患者被分为三个治疗组之一:持续OC疗法(30微克炔雌醇加150微克去氧孕烯)、周期OC疗法或每月注射一次促性腺激素释放激素激动剂(GnRH-a,醋酸亮丙瑞林长效制剂3.75毫克),为期3个月。在开始治疗前、治疗第3个月的第15至17天(研究1)以及第3个月的第26至28天(研究2)获取基础激素水平。在研究1和研究2期间还进行了GnRH刺激试验。
治疗3个月后,所有组的LH水平均显著下降,与持续OC组或GnRH-a组相比,周期OC组的抑制效果较差。仅在安慰剂治疗5至7天后,周期OC组的LH才出现显著升高(研究1与研究2)。在研究2期间,周期OC组的睾酮(T)也有所升高,而持续OC组和GnRH-a组的T水平持续受到抑制。尽管研究1与研究2中GnRH刺激后LH曲线下面积(AUC)测量值无显著差异,但在两项研究中,周期OC组的LH AUC均显著高于持续OC组或GnRH-a组。
周期OC组在安慰剂周期间LH分泌增加与T的相应增加有关。周期OC组在GnRH刺激后LH分泌的显著升高可能代表接受周期OC治疗的患者垂体敏感性增加,无论治疗周期处于哪个阶段,这可能是由于这些女性垂体中LH储备增加所致。